DMBT1 expression is down-regulated in breast cancer

Abstract

Background: We studied the expression of DMBT1 (deleted in malignant brain tumor 1), a putative tumor suppressor gene, in normal, proliferative, and malignant breast epithelium and its possible relation to cell cycle.

Genetic Mapping in Mice Identifies DMBT1 as a Candidate Modifier of Mammary Tumors and Breast Cancer Risk

“…(Table 3). As reported previously, 35,36 there was limited staining in tumor cells whereas the adjacent normal breast epithelium retained DMBT1 expression. We did not observe localized induction of DMBT1 in the breast epithelium immediately adjacent to the tumors as reported by Mollenhauer and coworkers.…”

“…DMBT1 was originally characterized as a gene deleted in malignant brain tumors 33 and down-regulated in breast cancer 35,36 as well as other cancers with epithelial origins, including cancers in the brain, skin, lung, and digestive tract. 33,[37][38][39] These studies indicate a potential role for DMBT1 as a tumor suppressor protein; however, DMBT1 has not previously been considered as a breast cancer susceptibility gene.…”

Effects of Muclin (Dmbt1) deficiency on the gastrointestinal system

“…There is a large body of literature supporting an association of DMBT1 with cancer (2,5,23,26,35,37). However, other studies have failed to provide a link between DMBT1 and cancer (20,40,41).…”

The Conserved Scavenger Receptor Cysteine-Rich Superfamily in Therapy and Diagnosis

“…Indeed, deregulation of DMBT1 expression has been reported for a number of tumors, including gliomas (Lin et al, 1998), small-and non-small-cell lung cancer cell lines and tumors (Takeshita et al, 1999;Wu et al, 1999;Mollenhauer et al, 2002), carcinoma of the esophagus (Mori et al, 1999;Mollenhauer et al, 2001), epithelial skin cancer , intrahepatic cholangiocarcinoma (Sasaki et al, 2003), breast cancer (Braidotti et al, 2004;Mollenhauer et al, 2004;Blackburn et al, 2007), salivary gland tumors (Bikker et al, 2004b), pancreatic ductal adenocarcinomas (Hustinx et al, 2004;Cheung et al, 2008), oral squamous cell carcinoma (Imai et al, 2005), gastric cancer (Conde et al, 2007), and cutaneous melanoma . In many cases, expression of DMBT1/gp340/SAG was deregulated not only at the tumor site but also in flanking tissue, which could arise as a consequence of the proinflammatory environment generated by the tumor.…”